基于分子建模的方法对强大的P2-P4宏循环抑制剂的型肝炎CNS3/4A蛋白酶
Nigel J Liverton1, M Katharine Holloway, John A McCauley
1Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. nigel_liverton@merck.com
Journal of the American Chemical Society
|March 15, 2008
概括
分子建模有助于设计新型C型肝炎病毒 (HCV) NS3蛋白酶抑制剂. 化合物25a表现出强烈的活性和有利的药理动力学,与现有的临床候选药物相比.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 病毒学 病毒学
背景情况:
- 肝炎C病毒 (HCV) NS3/4A蛋白酶是抗病毒疗法的关键标.
- 开发强效和选择性抑制剂对于HCV治疗至关重要.
- 分子建模已经成为药物发现的强大策略.
研究的目的:
- 设计和优化针对HCVNS3/4A蛋白酶的新型抑制剂.
- 为了评估化合物的体外活性,选择性和药理动力学特性.
主要方法:
- 利用分子建模来分析与抑制剂结合的HCV NS3/4A蛋白酶结构.
- 合成和优化初始抑制剂化合物.
- 在体外评估了抗病毒活性和对HCVNS3/4A蛋白酶的选择性.
- 在大鼠模型中评估了药理动力学参数.
主要成果:
- 分子建模指导了新一系列强效NS3蛋白酶抑制剂的设计.
- 优化工作导致了25a.化合物的鉴定.
- 化合物25a在体外表现出有希望的活性和选择性.
- 25a在老鼠中显示出有利的药理动力学特征.
结论:
- 分子建模是设计HCVNS3/4A蛋白酶抑制剂的有效工具.
- 化合物25a是进一步开发HCV治疗的有希望的候选物.
- 25a的有利特征表明它有可能成为临床NS3/4A蛋白酶抑制剂.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Molecular Models
43.8K
Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.
43.8K
Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Molecular Orbital Theory II
27.7K
Molecular Orbital Energy Diagrams
27.7K
Structure of Benzene: Molecular Orbital Model
12.7K
According to the molecular orbital (MO) model, benzene has a planar structure with a regular hexagon of six sp2 hybridized carbons. As shown in Figure 1, each carbon is bonded to three other atoms with C–C–C and H–C–C bond angles of 120°. The C–H bond length is 109 pm, and the C–C bond length is 139 pm which is midway between the single bond length of sp3 hybridized carbons (154 pm) and sp2 hybridized carbons (133 pm).
12.7K
Model Approaches for Pharmacokinetic Data: Physiological Models
279
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
279


